The Story of SLT

Article

How Dr Mark Latina pioneered Lumenis SLT technology

I have always had a strong interest in science, specifically chemistry. I attended Tufts University where I majored in chemistry with a minor in physics and mathematics.

Even though I had strong passion for chemistry, I was mostly interested in applying my scientific knowledge to helping people more directly; which is why I decided to attend medical school. I received my MD degree from the University of Connecticut and then returned to Boston to complete both my Ophthalmology residency and Glaucoma Fellowship at the Massachusetts Eye and Ear Infirmary, Harvard Medical School.

Based on the work of Dr Alvarado, and the evolving need to understand laser-tissue interactions, I decided to focus my research on approaches to 'selectively' target TM cells to better understand their role in the pathophysiology of glaucoma.

I received an NIH award to study photochemical targeting of TM cells. This was the beginning of the journey to the development of SLT. My research first focused on utilizing exogenous photosensitizers that would selectively be taken up (phagocytosed) by the TM cells. While this approach was effective in vitro it had little in vivo application. My approach then shifted to utilizing melanin as a photoabsorber to target TM cells.

Our research resulted in the seminal publication "Selective targeting of TM cell - In Vitro Studies of Pulsed and Continuous Wave laser interactions", which provided the fundamental parameters and description of laser-tissue interactions of pulsed vs CW lasers on TM cells. Based on this work, I hypothesized that it was not necessary to photocoagulate the TM to reduce IOP, but rather through selectively targeting pigmented TM cells, using short-pulsed, low-fluence lasers, one could achieve IOP reduction without causing thermal damage and scarring.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
© 2025 MJH Life Sciences

All rights reserved.